2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-117637
    ALS-I-41 1369357-99-2 98%
    ALS-I-41 is a novel, potent and selective oxytocin receptor antagonist with the potential to modulate biological activities related to social behavior and mental disorders. ALS-I-41 is being evaluated for behavioral pharmacology experiments in non-human primates and can be administered via intranasal or intramuscular injection. The central nervous system penetration and metabolic rate of ALS-I-41 were studied by mass spectrometry analysis in cerebrospinal fluid and plasma of macaque monkeys.
    ALS-I-41
  • HY-117646
    FG-5893 150527-23-4 98%
    FG-5893 is a 5-HT1A receptor agonist and a 5-HT2 receptor antagonist. FG-5893 has anxiolytic effect.
    FG-5893
  • HY-117670
    PD-161182 168570-35-2 98%
    PD-161182 is a non-peptide NK-3 antagonist. PD-161182 can be studied in NK-3-related central nervous system disturbances, pain, inflammation, pulmonary and skin diseases.
    PD-161182
  • HY-117694
    MK-8825 1380887-60-4 98%
    MK-8825 is an orally active, potent and selective CGRP receptor antagonist, which shows concentration-dependent inhibition of Capsaicin (HY-10448)-evoked dermal blood flow with an EC50 value of about 7.4 μM. MK-8825 inhibits CGRP-induced spontaneous nociceptive facial grooming behaviors, neuronal activation in the trigeminal nucleus, and systemic release of pro-inflammatory cytokines in a mouse model of acute orofacial masseteric muscle pain. MK-8825 is promising for research of acute migraine.
    MK-8825
  • HY-117714
    AZD-3161 1369501-46-1 98%
    AZD-3161 is a potent and selective blocker of NaV1.7 channel, with a pIC50 of 7.1. AZD-3161 can be used for the research of neuropathic and inflammatory pain.
    AZD-3161
  • HY-117739
    BRD1652 1597438-92-0 98%
    BRD1652 is a highly selective GSK3 inhibitor. BRD1652 can be used in the study of emotion-related diseases.
    BRD1652
  • HY-117764
    LSP4-2022 1413405-33-0 98%
    LSP4-2022 is a potent and brain-penetrant mGlu4-selective orthosteric agonist, with an EC50 of 0.11 μM. LSP4-2022 inhibits neurotransmission in cerebellar slices from wild-type but not mGlu4 receptor-knockout mice. LSP4-2022 shows pro-depressant activity.
    LSP4-2022
  • HY-117765
    RS-5773 129173-57-5 98%
    RS-5773 is a calcium channel inhibitor and a diltiazem congener. RS-5773 has antianginal effect and does not cause excessive hypotension or depression of atrioventricular conduction .
    RS-5773
  • HY-117774
    AHR-2244 hydrochloride 24677-84-7 98%
    AHR-2244 hydrochloride is a bioactive agent that acts against psychosis and anxiety. It selectively blocks CAR in mice, rats, and cats, and can reduce the lethality associated with amphetamine.
    AHR-2244 hydrochloride
  • HY-117785
    4’-Methoxy-α-ethylaminovalerophenone hydrochloride 17837-89-7 98%
    4’-Methoxy-α-ethylaminovalerophenone hydrochloride is structurally classified as a drug derivative.
    4’-Methoxy-α-ethylaminovalerophenone hydrochloride
  • HY-117787
    TUG-905 1390641-90-3 98%
    TUG-905 is a potent GPR40 agonist with an pEC50 value of 7.03. TUG-905 increases hypothalamic cell proliferation and survival. TUG-905 reduces body mass and increases the POMC mRNA expression.
    TUG-905
  • HY-117839
    PD-135666 134557-41-8 98%
    PD-135666 is a dipeptide inhibitor of cholecystokinin B (CCK B) receptors, binding to CCK B receptors in mouse cerebral cortex with IC50 of 0.1 nM. Its enantiomer, PD-140548, preferentially binds to CCK A receptors with IC50 of 2.8 nM in rat pancreas. PD-135666 exhibits anxiolytic effects in animal models.
    PD-135666
  • HY-117847
    LLY-2707 1621865-33-5 98%
    LLY-2707 is a selective glucocorticoid receptor (GR) antagonist. LLY-2707 is promising for research of diabetes and psychiatric disorders such as schizophrenia.
    LLY-2707
  • HY-117881
    CJ-15208 210236-47-8 98%
    CJ-15208 is a potent and selective κ-opioid receptor antagonist with significant opioid activity. CJ-15208 exhibited strong analgesic effects in the warm water tail withdrawal test in mice and was mediated through multiple opioid receptors. The stereoisomers of CJ-15208 exhibited different opioid activity characteristics, for example, one stereoisomer exhibited κ-opioid receptor antagonism, while the other exhibited δ-opioid receptor antagonism. All stereoisomers of CJ-15208 had no significant effects on respiration. The stereoisomers of CJ-15208 did not lead to the development of drug tolerance, which makes it potential in the further development of safe opioid analgesics.
    CJ-15208
  • HY-117891
    Davasaicin 147497-64-1 98%
    Davasaicin (KR 25018), Capsaicin (HY-10448) derivative, is an orally active analgesic agent.
    Davasaicin
  • HY-117936
    Muscarinic agonist 1 168818-83-5 98%
    Muscarinic agonist 1, AF267, functions by alleviating cognitive impairments.
    Muscarinic agonist 1
  • HY-117952
    L 743310 187724-86-3 98%
    L 743310 is a non-peptide, selective antagonist of the human neurokinin hNK1 receptor, with high affinity for primate and cloned human hNK1 receptors and lower affinity for rodent NK1 receptors. L 743310 inhibits resiniferatoxin-induced plasma protein extravasation in guinea pig esophagus. L 743310 has a dose-dependent inhibitory effect on cisplatin-induced emesis.
    L 743310
  • HY-117955
    GMA-839 162882-76-0 98%
    GMA-839 is a selective modulator of the γ-aminobutyric acid A receptor (GABAA) with an IC50 value of 230 nM. GMA-839 exhibits potent anxiolytic-like activity, demonstrating significant dose-dependent anxiolytic effects in animal models, with an effective oral dose of 1.6 mg/kg. Significant increases in punished responding were observed in squirrel monkeys and pigeons. GMA-839 shows promise for research in the field of anxiolytics.
    GMA-839
  • HY-117957
    BMS-932481 1263871-36-8 98%
    BMS-932481 is an orally active modulator for γ-secretase, selectively reduce Aβ1-42 and Aβ1-40 production, with IC50s of 6.6 and 25.3 nM, respectively.
    BMS-932481
  • HY-117979
    Alphadolone 14107-37-0 98%
    Alphadolone is a GABAA receptor positive allosteric modulator. Alphadolone has antinociceptive effects. Alphadolone causes general anaesthesia.
    Alphadolone
Cat. No. Product Name / Synonyms Application Reactivity